Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | CTSD | P07339 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | PGA5 | P0DJD9 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CTSE | P14091 | 1/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | CCKAR | P32238 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324788 | 1.00 | MLNR (0.58) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL6958382 | 1.00 | MLNR (0.58) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL6954624 | 1.00 | MLNR (0.58) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL6957401 | 1.00 | MLNR (0.58) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL6948749 | 0.93 | MLNR (0.49) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL6174510 | 0.90 | OPRD1 (0.58) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL7741786 | 0.88 | OPRD1 (0.56) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL6957092 | 0.88 | MLNR (0.49) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL12103377 | 0.86 | MLNR (0.64) | MLNRNR1I2ABCB11PGRCTSD | |
| SCHEMBL5909105 | 0.86 | OPRD1 (0.68) | MLNRNR1I2ABCB11PGRCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184989-A1 | De Novo Synthesis of Conjugates | NEKTAR THERAPEUTICS (US) | 2010-07-22 | — | — | US | claimed |
| JP-2010521465-A | — | — | 2010-06-24 | — | — | JP | claimed |
| EP-2125027-A2 | DE NOVO SYNTHESIS OF CONJUGATES | Nektar Therapeutics (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008112286-A9 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS AL CORP (US) | 2008-12-18 | — | — | WO | claimed |
| WO-2008112286-A2 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | claimed |
| CN-116730993-A | Teranavir intermediate and preparation method of Teranavir | 浙江科技学院 | 2023-09-12 | — | — | CN | disclosed |
| EP-2522367-B1 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2522367-B1 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9107956-B2 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-18 | — | — | US | disclosed |
| US-9107956-B2 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-18 | — | — | US | disclosed |
| US-9107956-B2 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2131865-B1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2008112286-A2 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112286-A2 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112289-A2 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070218486-A1 | Immunoassays, Haptens, Immunogens and Antibodies for Anti-HIV Therapeutics | ARK DIAGNOSTICS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070218486-A1 | Immunoassays, Haptens, Immunogens and Antibodies for Anti-HIV Therapeutics | ARK DIAGNOSTICS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007103740-A2 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | ARK DIAGNOSTICS (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184989-A1 | De Novo Synthesis of Conjugates | ABCG2, UGT1A8, SLC7A5 | MLNR 367/4885NR1I2 2182/4885ABCB11 59/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | MLNR 4092/4885NR1I2 4255/4885ABCB11 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.